TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1478293
Drug: Placebo (P),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (P), one i.v. injection of 50 ml of saline solution with the same schedule
Study: 29690924
Drug: Regularly dosed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regularly dosed paracetamol
Study: 23893147
Drug: Intradiscal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal and intraforaminal injection of oxygen‐ozone
Study: 23893147
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of oxygen‐ozone combined with 1ml of compound betamethasone
Study: 18829998
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (150 mg)
Study: 14604715
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with microkeratome blades wiped with balanced salt solution (BSS)
Study: 8742282
Drug: Intravenous regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous regional anesthesia
Study: 25850750
Drug: Selexipag (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selexipag (400 μg single dose)
Study: 25850750
Drug: Selexipag (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selexipag (600 μg multiple doses)
Study: 25850750
Drug: Selexipag (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selexipag (400 μg open-label dose)
Study: 23944767
Drug: Nonsynonymous m.10398A>G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsynonymous m.10398A>G mtDNA polymorphism (N=8)
Study: 17223112
Drug: rosuvastatin (across
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin (across dose range)
Study: 15470853
Drug: Kinetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinetic therapy (systematic mechanical rotation of patients with 40 degree turns)
Study: 7915703
Drug: Short-term prazosin
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term prazosin (2 mg orally)
Study: 7915703
Drug: Long-term prazosin
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term prazosin (5 mg/12 hr for 3 months)
Study: 769595
Drug: Intravenous atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atropine 0-3 mg given prior to surgery
Study: 769595
Drug: Droperidol 0-1
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Droperidol 0-1 mg/kg
Study: 769595
Drug: Atropine 0-6
Normalized name: atropine sulfate 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0-6 mg intramuscularly followed by controlled ventilation
Study: 28926521
Drug: TNT009 (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNT009 (7 consecutive cohorts, 0.3-100 mg/kg single doses)
Study: 28926521
Drug: TNT009 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNT009 (2 consecutive cohorts, 30 and 60 mg/kg per infusion, 4 weekly infusions)
Study: 24215780
Drug: Xylazine (1mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylazine (1mg/kg IV bolus followed by 0.69 mg/kg/h IV CRI for 2h)
Study: 24215780
Drug: Romifidine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romifidine (80 μg/kg IV bolus followed by 30 μg/kg/h IV CRI for 2h)
Study: 17106926
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor (ACE-I; Perindopril 4 mg/d)
Study: 17106926
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with interferon (IFN; 3 MU/L; 3 times a week) and ACE-I
Study: 17106926
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with ACE-I and IFN
Study: 11379810
Drug: BDP-extrafine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP-extrafine (400 microg daily)
Study: 11379810
Drug: FP (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP (400 microg daily)
Study: 7955168
Drug: Albendazole candy
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole candy 100 mg (single dose)
Study: 7955168
Drug: Albendazole 150
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 150 mg qd for two days
Study: 7955168
Drug: Albendazole 200
Normalized name: albendazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 200 mg qd for two days
Study: 24418865
Drug: 0.03% tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% tacrolimus ointment combined with 1% olopatadine ophthalmic solution
Study: 24418865
Drug: 0.03% tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% tacrolimus ointment combined with placebo eye drops
Study: 21039763
Drug: Pharmaceutical products
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical products with active substances classified by BCS
Study: 21039763
Drug: Pharmaceutical products
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical products with intra-subject variability higher than predicted
Study: 21039763
Drug: Comparisons between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparisons between pharmaceutical products from the four BCS classes
Study: 17060064
Drug: Angiotensin blocker
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin blocker (valsartan)
Study: 17060064
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (diltiazem monotherapy)
Study: 10936118
Drug: Salmeterol (42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (42 microg) every 12 h in addition to standard therapy
Study: 10936118
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two puffs every 12 h) in addition to standard therapy
Study: 18590407
Drug: NSAIDs in
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSAIDs in addition to opioid analgesics
Study: 17136232
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml of 0.5% lidocaine plus 20 mg propofol (Group P)
Study: 17136232
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml of 0.5% lidocaine (Group C)
Study: 10682869
Drug: Carbohydrate supplements
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate supplements
Study: 7595746
Drug: Etopophos (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etopophos (150 mg/m2, administered by constant rate infusion over 3.5 hours)
Study: 7595746
Drug: VePesid (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: VePesid (150 mg/m2, administered by constant rate infusion over 3.5 hours)
Study: 2275328
Drug: Flunitrazepam (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (0.04 mg.kg‐1)
Study: 7001862
Drug: Alprenolol (non-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprenolol (non-selective beta-blocker)
Study: 7001862
Drug: Metoprolol (cardioselective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (cardioselective beta 1-blocker)
Study: 17259500
Drug: Boric acid
Normalized name: Boric Acid
DrugBank: Boric acid (DB11326)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Boric acid vaginal suppositories (600 mg/day for 14 days)
Study: 17259500
Drug: Oral fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluconazole (150 mg single dose)
Study: 17259500
Drug: Clinical symptoms
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical symptoms and signs of VVC on the 15th day of treatment
Study: 7823668
Drug: Two blocks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two blocks of additional intensification therapy
Study: 7823668
Drug: One block
Normalized name: Adrenergic neurone blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: One block of intensification therapy at 5 weeks
Study: 7823668
Drug: One block
Normalized name: Adrenergic neurone blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: One block of intensification therapy at 20 weeks
Study: 7823668
Drug: No intensification
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intensification therapy
Study: 2688033
Drug: Active specific
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active specific immunotherapy (ASI) with an autologous tumor cell‐BCG vaccine
Study: 803910
Drug: Conventional plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional plus vasopressin therapy
Study: 31207009
Drug: Intermittent intrauterine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intrauterine balloon dilatation therapy at 2 weeks and 6 weeks after surgery
Study: 31207009
Drug: Intermittent intrauterine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intrauterine balloon dilatation therapy
Study: 23933032
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination capsule of Alfuzosin hydrochloride 10mg extended release and Solifenacin succinate 5mg
Study: 23933032
Drug: Individually administered
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually administered Xatral XL 10mg tablets (Alfuzosin) and Vesicare 5mg tablets (Solifenacin)
Study: 11043547
Drug: Repetitive peripheral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive peripheral magnetic stimulation (RPMS) treatment of the left forearm
Study: 9432635
Drug: Pantoprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (40 mg q.d. for 2 or 4 weeks)
Study: 9432635
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg q.d. for 2 or 4 weeks)
Study: 3885915
Drug: methylprednisolone, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylprednisolone, 30 mg/kg, every six hours for 48 hours
Study: 31785387
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) - four applications
Study: 31785387
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metronidazole (MTZ) and amoxicillin (AMX) - 3 tablets each for 7 days
Study: 29437170
Drug: Sacha inchi
Normalized name: Abies sachalinensis var. sachalinensis oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacha inchi oil (15 mL)
Study: 22111353
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume group (7 ml x kg(‐1) predicted body weight), n = 8
Study: 22111353
Drug: Conventional tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tidal volume group (10 ml x kg(‐1) predicted body weight), n = 8
Study: 17393617
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with drugs (treatment group)
Study: 11472316
Drug: Fructo oligosaccharides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructo oligosaccharides (10 g daily)
Study: 9935261
Drug: Intravenous alatrofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alatrofloxacin (200 or 300 mg/day) followed by oral trovafloxacin (200 mg/day)
Study: 9935261
Drug: Single-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intravenous or oral prophylaxis with alatrofloxacin or trovafloxacin
Study: 8186345
Drug: Oral mesalazine
Normalized name: mesalamine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mesalazine (5-aminosalicylic acid) 2.4 g/day
Study: 3364822
Drug: Methoxamine 10
Normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methoxamine 10 mg
Study: 554446
Drug: Thioridazine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine (100 to 600 mg daily)
Study: 554446
Drug: Drug holidays
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug holidays
Study: 26262996
Drug: Sublingual GSH
Normalized name: GSH
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual GSH
Study: 26262996
Drug: Oral GSH
Normalized name: GSH
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral GSH
Study: 18818130
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with cytokine-induced killer cells for 3 courses (CIK-I group)
Study: 18818130
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with cytokine-induced killer cells for 6 courses (CIK-II group)
Study: 11461949
Drug: Conventional-dose CsA
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose CsA (target trough level 300 ng/ml)
Study: 11461949
Drug: Low-dose CsA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CsA (target trough level 150 ng/ml)
Study: 11461949
Drug: Conventional-dose CsA
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose CsA
Study: 11461949
Drug: Low-dose CsA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CsA
Study: 2855478
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (2 litres, 0.9% NaCl) over 60 min
Study: 25577189
Drug: Dissonance‐based Counter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dissonance‐based Counter Attitudinal Therapy group treatment
Study: 23727190
Drug: Add-on pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Add-on pregabalin at a dosage of 600 mg/day
Study: 17255839
Drug: Lactoferrin-enhanced formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin-enhanced formula (850 mg/L)
Study: 17255839
Drug: Regular formula
Normalized name: COMPLEAT REGULAR FORMULA LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular formula (102 mg/L)
Study: 15284262
Drug: C+P (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: C+P (cisplatin 50 mg/m2 plus paclitaxel 135 mg/m2)
Study: 15284262
Drug: Cisplatin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (50 mg/m2)
Study: 9597213
Drug: 37.5 mg
Normalized name: pemoline 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5 mg ephedrine i.m.
Study: 30746344
Drug: Eicosapentaenoic Acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic Acid (EPA) 2 g/day
Study: 26197768
Drug: Chemotherapy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy or radiotherapy alone
Study: 22222177
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (sham treatment with disconnected ultrasound equipment)
Study: 21439960
Drug: High-dose pegylated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pegylated IFN-α2a (360 μg once per week or 180 μg twice per week) with ribavirin (1.0-1.2 or 1.2-1.6 g/d) for up to 72 weeks
Study: 21439960
Drug: High-dose pegylated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pegylated IFN-α with ribavirin
Study: 18505948
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy (intention-to-treat analysis)
Study: 16927381
Drug: Exposure-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based behavioral treatment
Study: 16927381
Drug: Non-exposure-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-exposure-based behavioral treatment
Study: 16927381
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (core treatment)
Study: 8808422
Drug: Ranitidine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 200 mg/day by continuous infusion
Study: 8808422
Drug: Ranitidine 400
Normalized name: ranitidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 400 mg/day by continuous infusion
Study: 30268713
Drug: Age-appropriate preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age-appropriate preparation for children undergoing radiotherapy
Study: 26621361
Drug: IFNgamma (human
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNgamma (human recombinant interferon 1 b gamma, trade name IMUKIN) administered in 3 subcutaneous escalating doses (100, 150 and 200 mug) over 4 weeks
Study: 25350474
Drug: Opioid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid treatment with an average of 144.5 ± 127.8 mg/d of MED, including 57.1% long-acting and 91.4% short-acting opioids.
Study: 25350474
Drug: Positive urine
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive urine drug tests (UDT) for illicit drugs or unprescribed medications (N = 15).
Study: 18936571
Drug: Postoperative glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative glucose levels between 110 to 200 mg/dL
Study: 18936571
Drug: Postoperative glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative glucose levels greater than 200 mg/dL
Study: 1936476
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and Glibenclamide
Study: 1936476
Drug: Metformin (long
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (long term therapy)
Study: 27503042
Drug: Hydroxyzine 50
Normalized name: hydroxyzine hydrochloride 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 50 mg (active control)
Study: 19699071
Drug: Nutraceutical combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical combination (NC) - 500 mg berberine, 200 mg red yeast rice, 10 mg policosanols
Study: 7794069
Drug: 0.2 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg/day recombinant human growth hormone (rhGH)
Study: 2218422
Drug: Pivmecillinam 700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam 700 mg t.i.d.
Study: 28810477
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and commitment therapy self-help intervention (self-help booklet and telephone support)
Study: 23783081
Drug: Quinvaxem(®) vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinvaxem(®) vaccine administered at 6, 10, and 14 weeks of age
Study: 23783081
Drug: Quinvaxem(®) vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinvaxem(®) vaccine
Study: 19057416
Drug: Herbal formula
Normalized name: Osteo Bi-Flex Joint Health Herbal Formula With Turmeric Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal formula (equivalent to 3,150 mg dry herb)
Study: 14615473
Drug: 10% oral
Normalized name: Xylocaine 10% Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% oral solution of levetiracetam (750 mg)
Study: 14615473
Drug: 750-mg tablet
Normalized name: levetiracetam 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750-mg tablet of levetiracetam
Study: 9589819
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 0.1%-salicylic acid 5% ointment
Study: 30773266
Drug: Liraglutide (aiming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (aiming at 3 mg daily for 12 weeks)
Study: 28103158
Drug: sumatriptan iontophoretic
Normalized name: Sumatriptan Iontophoretic Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: sumatriptan iontophoretic transdermal system (TDS)
Study: 28103158
Drug: 5‐HT1F receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐HT1F receptor agonist lasmiditan
Study: 28103158
Drug: 5‐HT2B and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐HT2B and 5‐HT7 receptor antagonism
Study: 25371534
Drug: HZ/su vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HZ/su vaccine (50 µg varicella-zoster virus glycoprotein E [gE] combined with AS01B adjuvant)
Study: 23547788
Drug: E. guineensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: E. guineensis leaf extract 500 mg
Study: 23547788
Drug: E. guineensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: E. guineensis leaf extract 1000 mg
Study: 23547788
Drug: F. deltoidea
Approvals — FDA: no, EMA: no, PMDA: no
Description: F. deltoidea leaf extract 1000 mg
Study: 20714991
Drug: Oral lutein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lutein supplementation
Study: 20714991
Drug: Fixed lutein/omega-3-fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed lutein/omega-3-fatty acid combination
Study: 20073226
Drug: Citrate-mosapride tablet
Normalized name: mosapride
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrate-mosapride tablet
Study: 11691566
Drug: Cefaclor (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (25 mg/kg/bid) for 5 days
Study: 11691566
Drug: Cefaclor (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (25 mg/kg/bid) for 10 days
Study: 9143642
Drug: Yohimbine 20
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine 20 mg once a day
Study: 9143642
Drug: Yohimbine 5
Normalized name: yohimbine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine 5 mg three times a day
Study: 9143642
Drug: Yohimbine 10
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine 10 mg three times a day
Study: 23460709
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m(2) on days 1, 22, and 43 combined with 70 Gy of radiotherapy (arm A)
Study: 23460709
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m(2) on days 1, 22, and 43 combined with 70 Gy of radiotherapy and erlotinib 150 mg per day (arm B)